Fosun Pharma boosts stake in subsidiary with $4.2m investment

Shanghai Fosun Pharmaceutical (Group) Co. (HKEX: 2196) announced a connected transaction where its subsidiary, Fosun Health, will invest RMB30 million (approximately $4.2 million USD) in cash into an unnamed target company in exchange for additional registered capital. This capital increase, detailed in an agreement dated February 20, 2025, will raise Fosun Health's stake in the target from 57.5363% to 67.1872%. Other shareholders, including Xingshuangjian Investment, Fosun Health Holding, and Zhuoye Health, will waive their preemptive rights.